RE: Corporate Presentation May 20269 Jun 2026 10:56
I’ve been thinking about the implications of the recent GENF presentation and the continued use of the term “trade sale” for the animal health program.
If the final SLAB data show:
* 24 aged beagles
* 5% reduction in methylation age
* p<0.05
* clean safety profile
* supportive frailty / functional data
then I think the market will have a hard time valuing the animal health asset at anything close to today’s ~£12M market cap.
The key point is that this would not be mouse data, cell data or a theoretical SIRT6 story anymore. It would be statistically significant biological age reversal in a large mammal using Genflow’s therapy.
If that is what the company is seeing internally, the repeated references to a potential trade sale start to make much more sense.
A buyer such as Zoetis, Merck Animal Health, Elanco or Boehringer would not care about GENF’s current market cap. They would care about the strategic value of obtaining exclusive rights to what could become the first commercially viable longevity platform in companion animals.
Even a relatively modest deal structure such as:
* $25M upfront
* $50M milestones
* 10% royalty
would already represent multiple times GENF’s current valuation before assigning any value to MASH, glaucoma, sarcopenia or the broader SIRT6 platform.
Obviously none of this is guaranteed and the SLAB data remain the critical catalyst. But if the methylation clock data are genuinely positive, I suspect investors are anchoring far too much on today’s market cap and not enough on what the asset could be worth to a strategic acquirer.
Sign In
Follow the stocks
